Comprehensive reagent toolkit for BRAF drug discovery. Select your modality below:
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Kinase | BRAF Wild-Type & Mutant Proteins (V600E, V600K, G469A, L597V, D594G). High purity (>95%), Endotoxin <1EU/ug, Sequence Verified. | View BRAF Products |
| Isoform Panel | BRAF WT / RAF1 / ARAF Protein Set for RAF isoform selectivity screening. Theoretical MW confirmed. | View BRAF Products |
| Gene Delivery | BRAF Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction (WT and mutant versions). | View BRAF Products |
| Benchmark Ab | Anti-BRAF (VE1 Clone Equivalent). Recombinant research-grade antibody recognizing V600E mutant. Sequence Verified. | View BRAF Products |
| Validator | BRAF siRNA Set for knockdown and specificity verification. | View BRAF Products |
| Related Target A | MEK1 (MAP2K1). Downstream effector for combination therapy and resistance assays. | View MEK1 Products |
| Related Target B | EGFR. Bypass resistance mechanism in BRAF-mutant colorectal cancer; critical combination partner. | View EGFR Products |
| Related Target C | NRAS. Upstream activator and primary resistance pathway; essential for paradoxical activation studies. | View NRAS Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Screening Drug-Resistant Mutants | Comprehensive Mutant Panel (V600E, V600K, Non-V600: G469A, L597V, D594G) with High Purity (>95%). |
| Paradoxical Activation Counter-Screening | CRAF / Wild-Type BRAF proteins strictly verified by mass spec; WT vs V600E available for mechanistic binding studies. |
| Isoform Selectivity Screening | BRAF/RAF1/ARAF homolog panel with >95% purity, verified by mass spec. |
| Lack of Reliable Pathway Controls / False Positives | Sequence Verified pathway targets (MEK, ERK) available; Validated siRNA included for specificity checks. |
| Combination Therapy Assays | MEK1/MEK2 proteins available for synergy studies. |
Live BRAF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BRAF therapeutics is intensifying, with major players shifting focus from first-generation V600E inhibitors (e.g., vemurafenib, dabrafenib) to next-generation pan-RAF and paradox-breaking agents. As first-generation therapies face resistance from mechanisms such as NRAS mutations, MEK reactivation, and EGFR bypass, the next wave of R&D targets RAF dimer disruption, PROTACs, and combination regimens with MEK and EGFR inhibitors. Key players include Novartis, Roche/Genentech, Pfizer (Array), and Day One Biopharmaceuticals. Clinical development is expanding from melanoma to colorectal cancer and NSCLC, where non-V600 mutations (Class II/III) represent an unmet need. High-purity mutant proteins and isoform panels are essential for selective inhibitor screening and paradoxical activation counter-screening.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Type I/II, Next-Gen) | Novartis, Roche, Pfizer, Day One | Melanoma, CRC, NSCLC | Selectivity Assay (Mutant vs WT Kinase Proteins) |
| Pan-RAF / Paradox Breaker | Novartis, Array/Pfizer, Takeda | Colorectal Cancer, Solid Tumors | Paradoxical Activation Assay (BRAF/RAF1/ARAF panel) |
| PROTAC / Degrader | BMS, Kymera, Arvinas, C4 Therapeutics | Refractory Solid Tumors | Ternary Complex Formation (High-purity full-length BRAF) |
| Combination Therapy | Roche, Novartis, Pierre Fabre | BRAF-mutant CRC, Melanoma | Pathway Interrogation (Need MEK1/2, EGFR reference antigens) |